These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11384205)

  • 1. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.
    Harro J; Tõnissaar M; Eller M
    Neuropeptides; 2001 Apr; 35(2):100-9. PubMed ID: 11384205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term blockade of CRF(1) receptors on exploratory behaviour, monoamines and transcription factor AP-2.
    Mällo T; Berggård C; Eller M; Damberg M; Oreland L; Harro J
    Pharmacol Biochem Behav; 2004 Apr; 77(4):855-65. PubMed ID: 15099932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
    Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
    Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
    Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M
    Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
    Bhutada P; Mundhada Y; Bansod K; Ubgade A; Quazi M; Umathe S; Mundhada D
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):955-60. PubMed ID: 20447436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
    Consoli D; Leggio GM; Mazzola C; Micale V; Drago F
    Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
    Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
    Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
    Overstreet DH; Keeney A; Hogg S
    Eur J Pharmacol; 2004 May; 492(2-3):195-201. PubMed ID: 15178365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of low dose N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine administration on exploratory and amphetamine-induced behavior and dopamine D2 receptor function in rats with high or low exploratory activity.
    Alttoa A; Kõiv K; Eller M; Uustare A; Rinken A; Harro J
    Neuroscience; 2005; 132(4):979-90. PubMed ID: 15857703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray.
    Martins AP; Marras RA; Guimarães FS
    Depress Anxiety; 2000; 12(2):99-101. PubMed ID: 11091933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression.
    Overstreet DH; Griebel G
    Eur J Pharmacol; 2004 Aug; 497(1):49-53. PubMed ID: 15321734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptide Y attenuates the effect of locus coeruleus denervation by DSP-4 treatment on social behaviour in the rat.
    Kask A; Eller M; Oreland L; Harro J
    Neuropeptides; 2000 Feb; 34(1):58-61. PubMed ID: 10688970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
    Revel L; Mennuni L; Garofalo P; Makovec F
    Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations.
    Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E
    J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to novelty and forced swimming evoke stressor-dependent changes in extracellular GABA in the rat hippocampus.
    de Groote L; Linthorst AC
    Neuroscience; 2007 Sep; 148(3):794-805. PubMed ID: 17693036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
    Ramamoorthy R; Radhakrishnan M; Borah M
    Behav Pharmacol; 2008 Feb; 19(1):29-40. PubMed ID: 18195592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.